Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective safety and efficacy study of intravenous SHED-CM in ALS
jRCT1031230719Recruiting
- Sponsor
- Hitonowa Medical
- Start
- Dec 2023
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of SHED-CM in amyotrophic lateral sclerosis (ALS), sponsored by Hitonowa Medical. Primary endpoint: Adverse events. Started Dec 2023; status: recruiting.
02
Drugs
SHED-CM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT1031230719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230719.